View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Ra Pharmaceuticals Inc: 2 directors sold/sold after exercising options

Two Directors at Ra Pharmaceuticals Inc sold/sold after exercising options 12,883 shares at between 44.250USD and 45.165USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: December 15, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Pr...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate and clinical developments. “We continue to make important progress in advancing our lead clinical candidate RA101495 SC in multiple, complement-mediated indications,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “While first generation treatments may address the basic mechanism of these diseases, the chall...

 PRESS RELEASE

Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that Doug Treco, Ph.D., President and Chief Executive Officer, will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:00 a.m. E.T. The conference is being held at the InterContinental Boston. A live webcast of the presentation can be ...

 PRESS RELEASE

Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG C...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design of its Phase 2 clinical trial of RA101495 SC as a treatment for generalized myasthenia gravis (gMG) will be presented in an oral platform presentation at the 70th Annual American Academy of Neurology (AAN), taking place April 21-27, 2018 in Los Angeles. “Despite current treatments, patients with gMG suffer from the progressive and debilitating burden of complement-mediated neuromuscular damage,” said James F. Howard, MD,...

 PRESS RELEASE

Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced the appointment of John C. King as Chief Commercial Officer, effective April 16, 2018. Mr. King brings to Ra Pharma more than 20 years of senior, global, commercial leadership experience within the biotechnology rare disease space, most recently with Alexion Pharmaceuticals. “H...

 PRESS RELEASE

Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focused on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced financial results for the fourth quarter and year ended December 31, 2017 and provided an update on recent corporate and clinical developments. “We made tremendous progress in 2017, advancing the development of our lead candidate, RA101495, a convenient, subcutaneous (SC), ...

 PRESS RELEASE

Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Hea...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that Doug Treco, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 8:40 a.m. E.T. The conference is being held at the Boston Marriott Copley Place. A live webcast of the presentation c...

Jonathan Moreland
  • Jonathan Moreland

Weekly Insider Tables: Mar 3, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

1A80 ACCELERATE DIAGNOSTICS INC.
BKD BROOKDALE SENIOR LIVING INC.
WFC WELLS FARGO & COMPANY
WAIR WESCO AIRCRAFT HOLDINGS INC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TTSH TILE SHOP HOLDINGS INC.
TRN TRINITY INDUSTRIES INC.
TNDM TANDEM DIABETES CARE INC
STOR STORE CAPITAL CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
PFLT PENNANTPARK FLOATING RATE CAPITAL LTD.
NLY ANNALY CAPITAL MANAGEMENT INC.
NIHD NII HOLDINGS INC
NHI NATIONAL HEALTH INVESTORS INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
LJPC LA JOLLA PHARMACEUTICAL COMPANY
IRT INDEPENDENCE REALTY TRUST INC.
IPHI INPHI CORPORATION
IMMU IMMUNOMEDICS INC.
GLPI GAMING AND LEISURE PROPERTIES INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FSIC FS KKR CAPITAL CORP.
FRSH PAPA MURPHYS HOLDINGS
FRGI FIESTA RESTAURANT GROUP INC.
EPC EDGEWELL PERSONAL CARE CO.
COTY COTY INC. CLASS A
CLDT CHATHAM LODGING TRUST
BDGE BRIDGE BANCORP INC.
AIMT AIMMUNE THERAPEUTICS INC
AAT AMERICAN ASSETS TRUST INC.
SLCA U.S. SILICA HOLDINGS INC.
CRC CALIFORNIA RESOURCES CORP
ADC AGREE REALTY CORPORATION
CBB CINCINNATI BELL INC.
CSV CARRIAGE SERVICES INC.
MLI MUELLER INDUSTRIES INC.
GRA W R GRACE & CO
MRAM EVERSPIN TECHNOLOGIES
RARX RA PHARMACEUTICALS
T AT&T CORP.
PI IMPINJ INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
CLIR CLEARSIGN TECHNOLOGIES CORP
BCO THE BRINK'S COMPANY
ODT ODONATE THERAPEUTICS INC
CTIC CELL THERAPEUTICS
SMPL INC.
CODA SIMPLY GOOD FOODS CO
XTNT CODA OCTOPUS GROUP INC.
DDR XTANT MEDICAL HOLDINGS
DEVELOPERS DIVERSIFIED REALTY CORPORATION
Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: Mar 1, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical T...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that the design of its Phase 2 clinical trial of RA101495 SC for the treatment of generalized myasthenia gravis (gMG) will be presented in an oral platform presentation at the 70th Annual American Academy of Neurology (AAN) Meeting, taking place April 21-27, 2018 in Los Angeles. The stu...

 PRESS RELEASE

Ra Pharma Supports 11th Annual Rare Disease Day® and Joins Global Mov...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today joins forces with 30 million health care advocates around the world for the 11th annual Rare Disease Day®. Rare Disease Day, which is always the last day of February, is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges p...

Jonathan Moreland
  • Jonathan Moreland

Weekly Insider Tables: Feb 24, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

UFI UNIFI INC
ZBH ZIMMER BIOMET HOLDINGS INC.
1A80 ACCELERATE DIAGNOSTICS INC.
DOV DOVER CORPORATION
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
WFC WELLS FARGO & COMPANY
VCEL VERICEL
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TDOC TELADOC HEALTH INC.
SBCF SEACOAST BANKING CORPORATION OF FLORIDA
PXLW PIXELWORKS INC.
OPK OPKO HEALTH INC.
NLY ANNALY CAPITAL MANAGEMENT INC.
NHI NATIONAL HEALTH INVESTORS INC.
MCHX MARCHEX INC. CL B
LJPC LA JOLLA PHARMACEUTICAL COMPANY
A2N6GQ LEGACY RESERVES
LC LENDINGCLUB CORP
JWN NORDSTROM INC.
IVAC INTEVAC INC.
IRT INDEPENDENCE REALTY TRUST INC.
IPHI INPHI CORPORATION
HII HUNTINGTON INGALLS INDUSTRIES INC.
HCAP HARVEST CAPITAL CREDIT CORP
HBAN HUNTINGTON BANCSHARES INCORPORATED
GOOD GLADSTONE COMMERCIAL CORPORATION
FLDM FLUIDIGM
EMC INSURANCE GROUP INC.
COBZ OVINTIV INC
CGNX COBIZ FINANCIAL
A2AM8Y COGNEX CORPORATION
BDGE CARDTRONICS PLC CLASS A
ARRS BRIDGE BANCORP INC.
AAT ARRIS INTERNATIONAL PLC
RVLT AMERICAN ASSETS TRUST INC.
CMG REVOLUTION LIGHTING TECHNOLOGIES
GRA CHIPOTLE MEXICAN GRILL INC.
CC W R GRACE & CO
RARX BIGLARI HOLDINGS A
NYMX CHEMOURS CO.
OLN RA PHARMACEUTICALS
EFR. NYMOX PHARMACEUTICAL CORP.
ODT OLIN CORPORATION
TEI EATON VANCE SENIOR FLOATING-RATE FUND
CCUR ODONATE THERAPEUTICS INC
RBNC TEMPLETON EMERGING MARKETS INCOME FUND
CLW CONCURRENT COMPUTER CORPORATION
MBL RELIANT BANCORP
SSTI CLEARWORKS.NET INC
KRMD M B T FINANCIAL CORP.
VRME SHOTSPOTTER
XTNT REPRO MED SYSTEMS
DDR VERIFYME
DIS XTANT MEDICAL HOLDINGS
DEVELOPERS DIVERSIFIED REALTY CORPORATION
THE WALT DISNEY COMPANY
Jonathan Moreland
  • Jonathan Moreland

Daily Insider Ratings Report: Feb 16, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Weekly Insider Tables: Feb 17, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch